Figure 4
(A) HeLa cells aggregated prior to drug treatment and (B) viability of HeLa cells in aggregates assessed with live/dead assay. (C) Average HeLa response curves for monolayers and aggregates 48 h post-treatment with vinblastine. (D) Average yeast response curves for monolayers and aggregates 48 h post-treatment with Amphotericin B (E) Drug concentration of drug (Vinblastine/AmB) in the middle of gel layer as a fraction of the applied concentration cmax, calculated from Eq. (3) with Dg = 3.3 × 10–10 m2/s and L = 300 µm. (F) Geometry of a single DEP array dot with cellular aggregate, L = 300 µm and d = 300 µm and the aggregate is modelled as a half sphere of diameter 0.46d. (G) Drug concentration of drug vinblastine in DEP gels as fraction of applied concentration cmax in a section through the centre of the cellular aggregate. Drug concentrations obtained by solving Eq. (3) in (i) a cellular aggregate region with Dc = 1.9 × 10–12 m2/s, k = 0.01 s−1 and (ii) a gel region with Dg = 3.3 × 10–10 m2/s and k = 0 s−1.
